Contraceptive suit still alive

defending the First Amendment against the Christian right ...

... because if Jews don't speak out, they'll think we don't mind

Web JewsOnFirst

Optional Member Code

Please email us
(click here)
catcher@JewsOnFirst.org

And "bookmark" us at
JewsOnFirst.org

Jews on First
P.O. Box 33821
Washington DC 20033

310-553-1146

Contraceptive suit still alive

Brooklyn judge refuses to dismiss a lawsuit looking to force the government to allow over-the-counter sales of the morning-after pill

BY Kathleen Kerr, Newsday.com, December 23, 2005

Brooklyn federal Judge Edward Korman refused yesterday to dismiss a lawsuit seeking to force the government to permit over-the-counter sales of a controversial emergency contraceptive pill.

Attorneys for the Manhattan-based Center for Reproductive Rights sued the federal government this past January on behalf of two advocacy organizations and nine women from a group called the Morning-After Pill Conspiracy. The lawsuit alleges that the Food and Drug Administration ignored a statutory deadline for deciding whether the pill, called Plan B, could be sold without a prescription.

Plan B, sometimes referred to as the morning-after pill, can prevent pregnancy if taken within 72 hours of having sex. Anti-abortion groups claim it causes abortions, while its manufacturer, Barr Pharmaceuticals, says it simply prevents pregnancy.

Conservatives and the anti-abortion lobby have pressured the Bush administration not to permit over-the-counter sales. The drug has been available by prescription since 1999.

Korman repeatedly questioned the FDA's failure to make a decision on nonprescription sales. "This has all the earmarks of an administrative agency filibuster," he said. "There's a serious issue here as to whether they're acting in good faith."

Assistant U.S. Attorney Franklin Amanat had objected to the lawsuit, arguing that the Center for Reproductive Rights did not have legal standing. Korman disagreed.

The lawsuit argues that the FDA violated women's constitutional rights to privacy and equal protection by failing to approve nonprescription sales.

The agency rejected Barr's application in May 2004 and this past August saying it needed more time to consider nonprescription sales to women younger than 17. Dr. Susan F. Wood, the FDA's top women's health officer, then resigned in protest.

Last month, the Government Accountability Office issued a report that found FDA officials made their initial decision even before the agency had finished reviewing the drug.

"The question here is [is] there some knowledge that FDA officials have about the safety of the drug," said Simon Heller, a staff attorney for the Center for Reproductive Rights.

Fair Use Statement: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.